Table 1. Inhibitors of PD-1 and PD-L1 in phase II and III clinical trials.
| Inhibitor | Other treatments in the study | Status | Identifier |
|---|---|---|---|
| Pembrolizumab* | Bemcentinib | Phase II, R | NCT03184558 |
| None | Phase II, R | NCT02411656 | |
| Anastrozole, doxorubicin, exemestane, letrozole | Phase II, R | NCT02648477 | |
| Valacyclovir, ADV/HSV-tk, radiation | Phase II, R | NCT03004183 | |
| Tavokinogene telseplasmid | Phase II, R | NCT03567720 | |
| Nab-paclitaxel, epirubicin, cyclophosphamide | Phase II, R | NCT03289819 | |
| Carboplatin, gemcitabine | Phase II, R | NCT02755272 | |
| None | Phase II, R | NCT03145961 | |
| Doxorubicin, cyclophosphamide, paclitaxel, carboplatin, decitabine | Phase II, R | NCT02957968 | |
| Carboplatin, docetaxel, pegfilgrastim | Phase II, R | NCT03639948 | |
| Enobosarm | Phase II, R | NCT02971761 | |
| Carboplatin, nab-paclitaxel | Phase II, R | NCT03121352 | |
| Radiation therapy | Phase III, R | NCT02954874 | |
| None | Phase II, ANR | NCT02447003 | |
| Capecitabine | Phase II, ANR | NCT03044730 | |
| Radiotherapy | Phase II, ANR | NCT02730130 | |
| Imprime PGG | Phase II, ANR | NCT02981303 | |
| Cyclophosphamide | Phase II, ANR | NCT02768701 | |
| Capecitabine, eribulin, gemcitabine, vinorelbine | Phase III, ANR | NCT02555657 | |
| Nab-paclitaxel, paclitaxel, gemcitabine, carboplatin, normal saline solution | Phase III, ANR | NCT02819518 | |
| Carboplatin, paclitaxel, doxorubicin, epirubicin, cyclophosphamide, placebo, filgrastim or pegfilgastrim | Phase III, ANR | NCT03036488 | |
| Cisplatin | Phase II, NR∥ | NCT03644589 | |
| Lenvatinib | Phase II, NR | NCT03797326 | |
| Carboplatin | Phase II, S (amendment) | NCT03213041 | |
| Nivolumab* | Cabozantinib | Phase II, R | NCT03316586 |
| Radiation therapy, low dose doxorubicin, cyclophosphamide, cisplatin | Phase II, R | NCT02499367 | |
| Ipilimumab | Phase II, R | NCT03546686 | |
| Capecitabine | Phase II, R | NCT03487666 | |
| Carboplatin | Phase II, R | NCT03414684 | |
| Ipilimumab, capecitabine | Phase II, NR | NCT03818685 | |
| Doxorubicin | Phase II, NR | NCT03815890 | |
| Toripalimab* | Nab-paclitaxel, placebo | Phase III, NR | NCT03777579 |
| Camrelizumab* | Apatinib | Phase II, R | NCT03394287 |
| Atezolizumab† | None | Phase II, R | NCT02478099 |
| Stereotactic radiosurgery | Phase II, R | NCT03483012 | |
| Paclitaxel, carbo/cyclo | Phase II, R | NCT01898117 | |
| Pegylated liposomal doxorubicin, cyclophosphamide, placebo | Phase II, R | NCT03164993 | |
| Placebo, paclitaxel | Phase III, R | NCT03125902 | |
| Placebo | Phase III, R | NCT03281954 | |
| Paclitaxel, dose-dense doxorubicin or dose-dense epirubicin, cyclophosphamide | Phase III, R | NCT03498716 | |
| Nab-paclitaxel, placebo | Phase III, ANR | NCT02425891 | |
| Placebo, nab-paclitaxel, doxorubicin, cyclophosphamide, filgrastim, pegfilgrastim | Phase III, ANR | NCT03197935 | |
| AZD6738, olaparib | Phase II, NR | NCT03740893 | |
| Capecitabine | Phase II, NR | NCT03756298 | |
| Carboplatin, paclitaxel | Phase II, S | NCT02883062 | |
| Durvalumab† | Olaparib | Phase II, R | NCT03167619 |
| Olaparib | Phase II, R | NCT03801369 | |
| Placebo, nab-paclitaxel, epirubicin, cyclophosphamide | Phase II, ANR | NCT02685059 | |
| Tremelimumab | Phase II, ANR | NCT02527434 | |
| Carboplatin, gemcitabine, nab-paclitaxel, personalized synthetic long peptide vaccine, poly ICLC | Phase II, NR | NCT03606967 | |
| AZD6738, olaparib | Phase II, NR | NCT03740893 |
Pembrolizumab, nivolumab, toripalimab and camrelizumab are anti-PD-1 drugs. Atezolizumab and durvalumab are anti-PD-L1 drugs.
PD-1 = programmed cell death protein 1; PD-L1 = programmed death-ligand 1; ADV/HSV-tk = adenoviral vector-mediated herpes simplex virus tyrosine kinase; R = recruiting; ANR = active, not recruiting; NR = not recruiting; S = suspended.
*Anti-PD-1; †Anti-PD-L1.